Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99343 | 0.86 | KDM4E (0.46) | KMT2ASMN1; SMN2DPP4KDM4EMEN1 | |
| SCHEMBL99917 | 0.81 | KMT2A (0.56) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL3476644 | 0.79 | KMT2A (0.62) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL99422 | 0.76 | KMT2A (0.65) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL16109055 | 0.75 | KMT2A (0.55) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL3476309 | 0.75 | KMT2A (0.61) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL99980 | 0.74 | KMT2A (0.63) | KMT2ASMN1; SMN2DPP4DPP9 | |
| SCHEMBL99100 | 0.74 | PSIP1 (0.59) | — | |
| SCHEMBL18597800 | 0.73 | SMN1; SMN2 (0.52) | KMT2ASMN1; SMN2DPP4KDM4ELMNA | |
| SCHEMBL99267 | 0.73 | KMT2A (0.65) | KMT2ASMN1; SMN2DPP4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | KMT2A 2903/4885SMN1; SMN2 3831/4885DPP4 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.